$0.54
4.07% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US68620A1043
Symbol
ONVO
Sector
Industry

Organovo Holdings, Inc. Stock price

$0.54
+0.00 0.41% 1M
-0.48 46.86% 6M
-0.57 51.17% YTD
-0.53 49.36% 1Y
-7.30 93.09% 3Y
-4.73 89.72% 5Y
-143.06 99.62% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.02 4.07%
ISIN
US68620A1043
Symbol
ONVO
Sector
Industry

Key metrics

Market capitalization $8.33m
Enterprise Value $3.43m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 49.00
P/S ratio (TTM) P/S ratio 119.00
P/B ratio (TTM) P/B ratio 1.17
Revenue growth (TTM) Revenue growth -83.60%
Revenue (TTM) Revenue $70.00k
EBIT (operating result TTM) EBIT $-14.28m
Free Cash Flow (TTM) Free Cash Flow $-12.35m
Cash position $6.19m
EPS (TTM) EPS $-1.38
P/S forward 49.00
EV/Sales forward 20.18
Short interest 0.93%
Show more

Is Organovo Holdings, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Organovo Holdings, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Organovo Holdings, Inc.:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Organovo Holdings, Inc.:

Hold
100%

Financial data from Organovo Holdings, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
0.07 0.07
84% 84%
100%
- Direct Costs 0.28 0.28
10% 10%
400%
-0.21 -0.21
262% 262%
-300%
- Selling and Administrative Expenses 8.78 8.78
4% 4%
12,543%
- Research and Development Expense 5 5
47% 47%
7,143%
-14 -14
24% 24%
-20,000%
- Depreciation and Amortization 0.28 0.28
10% 10%
400%
EBIT (Operating Income) EBIT -14 -14
24% 24%
-20,396%
Net Profit -14 -14
23% 23%
-19,986%

In millions USD.

Don't miss a Thing! We will send you all news about Organovo Holdings, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Organovo Holdings, Inc. Stock News

Neutral
GlobeNewsWire
about 2 months ago
SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announced that Executive Chairman Keith Murphy presented on the company's near and long-term outlook, operational plans, at the Jones Trading Healthcare ...
Neutral
GlobeNewsWire
4 months ago
Poster presented at DDW2024 demonstrating the potential of the Company's clinical-stage compound, FXR314, in combination with tofacitinib for treating IBD.
Neutral
GlobeNewsWire
4 months ago
Organovo will be presenting data on the Company's lead clinical-stage drug, FXR314 during DDW2024, which is being held in Washington, D.C. May 18-21, 2024
More Organovo Holdings, Inc. News

Company Profile

Organovo Holdings, Inc. engages in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary NovoGen Bioprinters and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company was founded on January 30, 2012 and is headquartered in San Diego, CA.

Head office United States
CEO Keith Murphy
Employees 20
Founded 2012
Website www.organovo.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today